

Nicola A Hanania

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8659176/publications.pdf>

Version: 2024-02-01

338
papers

17,223
citations

19657

61
h-index

17592

121
g-index

345
all docs

345
docs citations

345
times ranked

14247
citing authors

#	ARTICLE	IF	CITATIONS
1	Lebrikizumab Treatment in Adults with Asthma. <i>New England Journal of Medicine</i> , 2011, 365, 1088-1098.	27.0	1,418
2	Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. <i>Annals of Internal Medicine</i> , 2011, 155, 179.	3.9	896
3	Exploring the Effects of Omalizumab in Allergic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 804-811.	5.6	772
4	Anxiety and Depression in COPD. <i>Chest</i> , 2008, 134, 43S-56S.	0.8	574
5	Omaliuzumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy. <i>Annals of Internal Medicine</i> , 2011, 154, 573.	3.9	460
6	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. <i>Lancet Respiratory Medicine</i> , 2016, 4, 781-796.	10.7	398
7	Chronic Obstructive Pulmonary Disease Exacerbations in the COPD Gene Study: Associated Radiologic Phenotypes. <i>Radiology</i> , 2011, 261, 274-282.	7.3	373
8	Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. <i>Thorax</i> , 2015, 70, 748-756.	5.6	343
9	The Efficacy and Safety of Fluticasone Propionate (250 µg)/Salmeterol (50 µg) Combined in the Diskus Inhaler for the Treatment of COPD. <i>Chest</i> , 2003, 124, 834-843.	0.8	313
10	Radiation-Induced Lung Injury. <i>Chest</i> , 2019, 156, 150-162.	0.8	313
11	Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2013, 1, 210-223.	10.7	301
12	Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 1295-1302.e3.	2.9	288
13	Revisiting high and low airway inflammation in asthma: current knowledge and therapeutic implications. <i>Clinical and Experimental Allergy</i> , 2017, 47, 161-175.	2.9	287
14	Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 604-611.	5.6	250
15	Adverse effects of inhaled corticosteroids. <i>American Journal of Medicine</i> , 1995, 98, 196-208.	1.5	239
16	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	5.7	232
17	Prevention of Acute Exacerbations of COPD. <i>Chest</i> , 2015, 147, 894-942.	0.8	230
18	Medical Personnel's Knowledge of and Ability to Use Inhaling Devices. <i>Chest</i> , 1994, 105, 111-116.	0.8	226

#	ARTICLE	IF	CITATIONS
19	Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 324-330.	5.6	221
20	Omalizumab in Asthma: An Update on Recent Developments. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 525-536.e1.	3.8	179
21	Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 1995, 96, 571-579.	2.9	163
22	EAACI Biologicals Guidelinesâ€”Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	5.7	156
23	The effects of cigarette smoke on airway inflammation in asthma and COPD: Therapeutic implications. <i>Respiratory Medicine</i> , 2012, 106, 319-328.	2.9	153
24	A Combined Pulmonary-Radiology Workshop for Visual Evaluation of COPD: Study Design, Chest CT Findings and Concordance with Quantitative Evaluation. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 151-159.	1.6	143
25	Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1252-1258.e1.	2.9	139
26	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2037-2047.e10.	2.9	138
27	Efficacy and safety of once-daily single-inhaler triple therapy (FF/LUMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 69-84.	10.7	135
28	Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPD Gene Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1397-1405.	5.6	132
29	Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. <i>Annals of the American Thoracic Society</i> , 2015, 12, 27-34.	3.2	131
30	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 516-526.	3.8	123
31	The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 134-141.	2.6	121
32	Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 212-227.	2.5	117
33	Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. <i>Chest</i> , 2017, 151, 68-77.	0.8	113
34	COPD Gene 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 384-399.	0.7	112
35	β_2 -Agonist Intrinsic Efficacy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1353-1358.	5.6	108
36	β_2 -Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2435-2440.	7.1	104

#	ARTICLE	IF	CITATIONS
37	The Efficacy and Safety of the Novel Long-Acting \hat{I}^2 2 Agonist Vilanterol in Patients With COPD. <i>Chest</i> , 2012, 142, 119-127.	0.8	96
38	Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 717-724.	2.9	93
39	COVID-19, asthma, and biological therapies: What we need to know. <i>World Allergy Organization Journal</i> , 2020, 13, 100126.	3.5	90
40	Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 107, 65-70.	1.0	89
41	Periostin, a novel biomarker of TH2-driven asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 60-65.	2.6	88
42	Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. <i>PLoS Genetics</i> , 2016, 12, e1006011.	3.5	88
43	Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. <i>Intensive Care Medicine</i> , 2021, 47, 1258-1270.	8.2	88
44	Regression of a Plasmablastic Lymphoma in a Patient with HIV on Highly Active Antiretroviral Therapy. <i>Leukemia and Lymphoma</i> , 2002, 43, 423-426.	1.3	87
45	Predicting episodes of poor asthma control in treated patients with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 1226-1233.	2.9	87
46	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines & recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1043-1057.	5.7	85
47	An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2064-2077.	3.2	82
48	Bronchodilator Reversibility in COPD. <i>Chest</i> , 2011, 140, 1055-1063.	0.8	80
49	Care pathways for the selection of a biologic in severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1701782.	6.7	79
50	Clinical and Economic Burden of Depression/Anxiety in Chronic Obstructive Pulmonary Disease Patients within a Managed Care Population. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 293-299.	1.6	78
51	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017, 14, 552-563.	1.6	77
52	Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. <i>Respiratory Research</i> , 2011, 12, 6.	3.6	76
53	Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. <i>Respiratory Medicine</i> , 2011, 105, 1516-1522.	2.9	72
54	Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. <i>Respiratory Medicine</i> , 2012, 106, 91-101.	2.9	72

#	ARTICLE	IF	CITATIONS
55	Targeting Airway Inflammation in Asthma. <i>Chest</i> , 2008, 133, 989-998.	0.8	71
56	<p>Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1127-1138.	2.3	71
57	<i>Staphylococcus aureus</i> and its IgE-inducing enterotoxins in asthma: current knowledge. <i>European Respiratory Journal</i> , 2020, 55, 1901592.	6.7	71
58	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€™ Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1058-1068.	5.7	67
59	Role of T2 inflammation biomarkers in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 59-68.	2.6	65
60	Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). <i>Respiratory Medicine</i> , 2010, 104, 1160-1170.	2.9	64
61	Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 526-534.	3.5	63
62	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspensionâ„¢ Delivery Technology in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017, 126, 105-115.	2.9	63
63	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020, 6, 47-66.	2.2	63
64	Factors Associated With Emergency Department Dependence of Patients With Asthma. <i>Chest</i> , 1997, 111, 290-295.	0.8	61
65	Racial Differences in Quality of Life in Patients With COPD. <i>Chest</i> , 2011, 140, 1169-1176.	0.8	61
66	Long-term Course of Depression Trajectories in Patients With COPD. <i>Chest</i> , 2016, 149, 916-926.	0.8	61
67	Nebulized arformoterol in patients with COPD: A 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. <i>Clinical Therapeutics</i> , 2007, 29, 261-278.	2.5	60
68	The Asthma COPD Overlap Syndrome (ACOS). <i>Current Allergy and Asthma Reports</i> , 2015, 15, 509.	5.3	59
69	A Simplified Score to Quantify Comorbidity in COPD. <i>PLoS ONE</i> , 2014, 9, e114438.	2.5	58
70	Blocking KV1.3 Channels Inhibits Th2 Lymphocyte Function and Treats a Rat Model of Asthma. <i>Journal of Biological Chemistry</i> , 2014, 289, 12623-12632.	3.4	58
71	Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2017, 23, 696-704.	2.1	57
72	ACCIDENTAL HYPOTHERMIA. <i>Critical Care Clinics</i> , 1999, 15, 235-249.	2.6	56

#	ARTICLE	IF	CITATIONS
73	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 294-302.	5.6	56
74	Salmeterol Stimulation Dissociates β 2-Adrenergic Receptor Phosphorylation and Internalization. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 254-261.	2.9	54
75	Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Current Opinion in Pulmonary Medicine, 2010, 16, 1-5.	2.6	54
76	Clinical Epidemiology of COPD. Chest, 2019, 156, 228-238.	0.8	53
77	Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation. Antioxidants, 2022, 11, 50.	5.1	53
78	COPD in the Elderly Patient. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 596-606.	2.1	52
79	Executive Summary. Chest, 2015, 147, 883-893.	0.8	51
80	Targeting IgE in asthma. Current Opinion in Pulmonary Medicine, 2012, 18, 1-5.	2.6	49
81	Validity and Responsiveness of the Depression Anxiety Stress Scales-21 (DASS-21) in COPD. Chest, 2019, 155, 1166-1177.	0.8	49
82	A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. American Journal of Emergency Medicine, 2006, 24, 259-267.	1.6	48
83	The safety of long-acting β 2-agonists in the treatment of stable chronic obstructive pulmonary disease. International Journal of COPD, 2013, 8, 53.	2.3	48
84	A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges. International Journal of COPD, 2015, 10, 725.	2.3	48
85	Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. International Journal of COPD, 2010, 5, 1-10.	2.3	48
86	The Accuracy of a Handheld Portable Spirometer. Chest, 1996, 109, 152-157.	0.8	46
87	Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. Cleveland Clinic Journal of Medicine, 2018, 85, S11-S18.	1.3	46
88	Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. Metabolism: Clinical and Experimental, 2011, 60, 1449-1455.	3.4	45
89	Age-related differences in asthma outcomes in the United States, 1988-2006. Annals of Allergy, Asthma and Immunology, 2013, 110, 240-246.e1.	1.0	45
90	β 2-Adrenoceptor inverse agonists in asthma. Current Opinion in Pharmacology, 2010, 10, 254-259.	3.5	44

#	ARTICLE	IF	CITATIONS
91	Predictive Biomarkers for Asthma Therapy. <i>Current Allergy and Asthma Reports</i> , 2017, 17, 69.	5.3	44
92	Trends in 30-day readmission rates after COPD hospitalization, 2006–2012. <i>Respiratory Medicine</i> , 2017, 130, 92-97.	2.9	44
93	Targeting the interleukin-4 and interleukin-13 pathways in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 50-55.	2.6	44
94	Clinical Approach to the Therapy of Asthma-COPD Overlap. <i>Chest</i> , 2019, 155, 168-177.	0.8	44
95	One hundred years of chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2007, 101, 1049-1065.	2.9	43
96	Asthma in the elderly: current knowledge and future directions. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 55-59.	2.6	43
97	Acute asthma in pregnancy. <i>Critical Care Medicine</i> , 2005, 33, S319-S324.	0.9	42
98	The impact of inhaled corticosteroid and long-acting β_2 -agonist combination therapy on outcomes in COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 540-550.	2.6	42
99	Racial Differences in CT Phenotypes in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 20-27.	1.6	42
100	Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1629-1633.e2.	2.9	42
101	Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 100.	2.4	41
102	Age-Related Differences in Health-Related Quality of Life in COPD. <i>Chest</i> , 2016, 149, 927-935.	0.8	41
103	Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. <i>Drug Safety</i> , 2018, 41, 489-509.	3.2	41
104	Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2019, 16, 826-835.	3.2	41
105	Asthma in Older Adults. <i>Clinics in Chest Medicine</i> , 2007, 28, 685-702.	2.1	40
106	The St. George's Respiratory Questionnaire Definition of Chronic Bronchitis May Be a Better Predictor of COPD Exacerbations Compared With the Classic Definition. <i>Chest</i> , 2019, 156, 685-695.	0.8	40
107	Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 565-576.e1.	1.0	40
108	Comorbidities of COPD Have a Major Impact on Clinical Outcomes, Particularly in African Americans. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 1, 105-114.	0.7	40

#	ARTICLE	IF	CITATIONS
109	Gender Differences of Airway Dimensions in Anatomically Matched Sites on CT in Smokers. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 285-292.	1.6	38
110	Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1025-1031.e2.	3.8	38
111	Anti-Inflammatory Activities of β_2 -Agonists. Inflammation and Allergy: Drug Targets, 2004, 3, 271-277.	3.1	37
112	Effect of Nebulized Arformoterol on Airway Function in COPD: Results from Two Randomized Trials. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 25-34.	1.6	36
113	Comparative Effectiveness of Noninvasive Ventilation vs Invasive Mechanical Ventilation in Chronic Obstructive Pulmonary Disease Patients With Acute Respiratory Failure. Journal of Hospital Medicine, 2013, 8, 165-172.	1.4	36
114	Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2016, 13, 1016-1025.	3.2	36
115	Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. Chest, 2018, 153, 65-76.	0.8	36
116	The Association of Depressive Symptoms With Rates of Acute Exacerbations in Patients With COPD: Results From a 3-year Longitudinal Follow-up of the ECLIPSE Cohort. Journal of the American Medical Directors Association, 2017, 18, 955-959.e6.	2.5	35
117	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respiratory Medicine, 2019, 154, 86-92.	2.9	35
118	Immunological biomarkers in severe asthma. Seminars in Immunology, 2019, 46, 101332.	5.6	35
119	Efficacy and Safety of Nebulized Formoterol as Add-on Therapy in COPD Patients Receiving Maintenance Tiotropium Bromide. Drugs, 2009, 69, 1205-1216.	10.9	32
120	Ten years of tiotropium: clinical impact and patient perspectives. International Journal of COPD, 2013, 8, 117.	2.3	32
121	Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2018, 15, 926-934.	3.2	32
122	Acute asthma in pregnancy. Critical Care Clinics, 2004, 20, 731-745.	2.6	31
123	The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 111-123.	0.7	31
124	Cognitive-Behavioral Therapy for Chronic Cardiopulmonary Conditions. Primary Care Companion To the Journal of Clinical Psychiatry, 2010, 12, .	0.6	31
125	Vitamin D and asthma. Current Opinion in Pulmonary Medicine, 2011, 17, 1-5.	2.6	29
126	Perceptions and Attitudes Toward the Use of Nebulized Therapy for COPD: Patient and Caregiver Perspectives. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 482-492.	1.6	29

#	ARTICLE	IF	CITATIONS
127	Association of Triglyceride-Glucose Index and Lung Health. <i>Chest</i> , 2021, 160, 1026-1034.	0.8	29
128	Glucose and pyruvate metabolism in severe chronic obstructive pulmonary disease. <i>Journal of Applied Physiology</i> , 2012, 112, 42-47.	2.5	28
129	Role of biologics targeting type 2 airway inflammation in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 3-11.	2.6	28
130	<p>Targeting IL-5 in COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 1045-1051.	2.3	28
131	How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1081-1088.	3.8	28
132	Treatments for COPD. <i>Respiratory Medicine</i> , 2005, 99, S28-S40.	2.9	27
133	VASODILATORS IN MECHANICAL VENTILATION. <i>Critical Care Clinics</i> , 1998, 14, 611-627.	2.6	26
134	The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: An eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. <i>Clinical Therapeutics</i> , 2005, 27, 531-542.	2.5	26
135	The role of intrinsic efficacy in determining response to a β_2 -agonist in acute severe asthma. <i>Respiratory Medicine</i> , 2007, 101, 1007-1014.	2.9	26
136	Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 414-418.e1.	1.0	26
137	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2020, 75, 935-945.	1.9	25
138	VENTILATION OF PATIENTS WITH ASTHMA AND OBSTRUCTIVE LUNG DISEASE. <i>Critical Care Clinics</i> , 1998, 14, 685-705.	2.6	24
139	Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. <i>Respiratory Care</i> , 2018, 63, 833-839.	1.6	24
140	How does race/ethnicity influence pharmacological response to asthma therapies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 435-446.	3.3	24
141	The Hospital Readmissions Reduction Program and Readmissions for Chronic Obstructive Pulmonary Disease, 2006â€“2015. <i>Annals of the American Thoracic Society</i> , 2020, 17, 450-456.	3.2	24
142	Effect of Exposure to Low Levels of Ozone on the Response to Inhaled Allergen in Allergic Asthmatic Patients. <i>Chest</i> , 1998, 114, 752-756.	0.8	23
143	The Safety and Efficacy of Arformoterol and Formoterol in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 7, 17-31.	1.6	23
144	New bronchodilators. <i>Current Opinion in Pharmacology</i> , 2012, 12, 238-245.	3.5	23

#	ARTICLE	IF	CITATIONS
145	Effect of a Primary Care Continuing Education Program on Clinical Practice of Chronic Obstructive Pulmonary Disease: Translating Theory Into Practice. <i>Mayo Clinic Proceedings</i> , 2012, 87, 862-870.	3.0	22
146	Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. <i>Respiratory Medicine</i> , 2014, 108, 366-375.	2.9	22
147	One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD. <i>Chest</i> , 2014, 146, 1531-1542.	0.8	22
148	Long-Term Benefits of Pulmonary Rehabilitation in Patients With COPD. <i>Chest</i> , 2021, 159, 967-974.	0.8	22
149	Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. <i>Clinical Therapeutics</i> , 2008, 30, 989-1002.	2.5	21
150	Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and 2). <i>Overlock 101Tf 50 537</i>		
151	Biological treatments for severe asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 379-386.	2.3	21
152	Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - A cross sectional analysis of the COPD Gene cohort. <i>Journal of Psychosomatic Research</i> , 2019, 118, 18-26.	2.6	21
153	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 313-323.	5.6	21
154	Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 410-419.	3.8	21
155	Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 199-208.	2.6	20
156	Budesonide/formoterol combination in COPD: a US perspective. <i>International Journal of COPD</i> , 2010, 5, 357.	2.3	20
157	The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. <i>Chest</i> , 2016, 150, 188-195.	0.8	20
158	Medical Personnel's Knowledge of the Ability to Use Inhaling Devices. <i>Chest</i> , 1995, 107, 290.	0.8	19
159	Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. <i>Current Opinion in Internal Medicine</i> , 2005, 4, 311-316.	1.5	19
160	Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire. <i>Mayo Clinic Proceedings</i> , 2011, 86, 375-381.	3.0	19
161	Obesity modulates diaphragm curvature in subjects with and without COPD. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 313, R620-R629.	1.8	19
162	Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 633-643.e1.	3.8	19

#	ARTICLE	IF	CITATIONS
163	Management of Life-Threatening Asthma. <i>Chest</i> , 2022, 162, 747-756.	0.8	19
164	A Unified Front Against COPD. <i>Chest</i> , 2011, 140, 565-566.	0.8	18
165	IgE-mediated asthma: New revelations and future insights. <i>Respiratory Medicine</i> , 2016, 112, 128-129.	2.9	18
166	Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. <i>Thorax</i> , 2020, 75, 735-743.	5.6	18
167	Evaluation of Obstructive Lung Disease with Vibration Response Imaging. <i>Journal of Asthma</i> , 2008, 45, 923-930.	1.7	17
168	Optimizing safety of COPD treatments: role of the nurse practitioner. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 53.	2.7	17
169	Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB402.	2.9	17
170	Implications of Marijuana Decriminalization on the Practice of Pulmonary, Critical Care, and Sleep Medicine. A Report of the American Thoracic Society Marijuana Workgroup. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1700-1710.	3.2	17
171	Antifungals in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 48-54.	2.6	17
172	Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 256-266.	1.4	17
173	Characteristics and outcomes of older adults with long-standing versus late-onset asthma. <i>Journal of Asthma</i> , 2017, 54, 223-229.	1.7	17
174	Health-Care Utilization After Near-Fatal Asthma. <i>Chest</i> , 1995, 107, 1564-1569.	0.8	16
175	Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD care. <i>International Journal of COPD</i> , 2011, 6, 297.	2.3	16
176	Assessing biomarkers in a real-world severe asthma study (ARIETTA). <i>Respiratory Medicine</i> , 2016, 115, 7-12.	2.9	16
177	<p>Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 301-307.	1.9	16
178	Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2630-2639.e6.	3.8	16
179	The impact of fungal allergic sensitization on asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 3-8.	2.6	16
180	Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 45-53.	2.6	16

#	ARTICLE	IF	CITATIONS
181	The many faces of asthma-chronic obstructive pulmonary disease overlap. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 1-10.	2.6	15
182	Targeting lipid mediators in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 121-127.	2.6	15
183	Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 222-228.	3.8	15
184	Depressive and anxiety symptoms in patients with COPD: A network analysis. <i>Respiratory Medicine</i> , 2022, 198, 106865.	2.9	15
185	Pulmonary-renal syndromes in the intensive care unit. <i>Critical Care Clinics</i> , 2002, 18, 881-895.	2.6	14
186	Safety of Chronic Obstructive Pulmonary Disease Medications: A Primary Care Perspective. <i>Postgraduate Medicine</i> , 2011, 123, 72-79.	2.0	14
187	Precision medicine and treatable traits in chronic airway diseases - where do we stand?. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 33-39.	2.6	14
188	The role of combination therapy with corticosteroids and long-acting β_2 -agonists in the prevention of exacerbations in COPD. <i>International Journal of COPD</i> , 2006, 1, 345-354.	2.3	14
189	Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. <i>Respiratory Care</i> , 2018, 63, 840-848.	1.6	13
190	Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 507-515.e10.	3.8	13
191	A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. <i>Respiratory Medicine</i> , 2014, 108, 1310-1320.	2.9	12
192	Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD. <i>International Journal of COPD</i> , 2021, Volume 16, 2515-2522.	2.3	11
193	Optimizing Maintenance Therapy for Chronic Obstructive Pulmonary Disease: Strategies for Improving Patient-Centered Outcomes. <i>Clinical Therapeutics</i> , 2007, 29, 2121-2133.	2.5	10
194	Hospital management of acute exacerbations of chronic obstructive pulmonary disease. <i>Journal of Hospital Medicine</i> , 2015, 10, 328-339.	1.4	10
195	The road to precision medicine in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 1-3.	2.6	10
196	Bayesian inference of networks across multiple sample groups and data types. <i>Biostatistics</i> , 2020, 21, 561-576.	1.5	10
197	Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 743-752.	3.4	10
198	COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. <i>Journal of Family Practice</i> , 2018, 67, S11-S18.	0.2	10

#	ARTICLE	IF	CITATIONS
199	Revisiting asthma control: How should it best be defined?. Pulmonary Pharmacology and Therapeutics, 2007, 20, 483-492.	2.6	9
200	Update on the Pharmacologic Therapy for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2007, 28, 589-607.	2.1	9
201	It's about time "directing our attention toward modifying the course of COPD. Respiratory Medicine, 2008, 102, S37-S48.	2.9	9
202	Measuring Competence in Metered Dose Inhaler Use Using Capmedic Electronic Inhaler Monitoring Tool. Chest, 2016, 150, 14A.	0.8	9
203	Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respiratory Medicine, 2016, 111, 30-38.	2.9	9
204	Controversies and opportunities in severe asthma. Current Opinion in Pulmonary Medicine, 2018, 24, 83-93.	2.6	9
205	Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. Expert Review of Respiratory Medicine, 2021, 15, 153-159.	2.5	9
206	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. Journal of Inflammation, 2021, 18, 17.	3.4	9
207	Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2017, 4, 7-20.	0.7	9
208	A Risk Prediction Model for Mortality Among Smokers in the COPD Gene Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 346-361.	0.7	9
209	Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Advances in Therapy, 2009, 26, 1024-1034.	2.9	8
210	Role of anticholinergics in asthma management. Current Opinion in Pulmonary Medicine, 2015, 21, 103-108.	2.6	8
211	Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Review of Respiratory Medicine, 2016, 10, 767-780.	2.5	8
212	Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. Journal of the American Medical Directors Association, 2017, 18, 1063-1068.	2.5	8
213	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. Journal of Asthma, 2021, 58, 849-854.	1.7	8
214	Assessing Patient and Provider Perceptions of Factors Associated with Patient Engagement in Asthma Care. Annals of the American Thoracic Society, 2017, 14, 659-666.	3.2	7
215	Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study. Journal of Allergy and Clinical Immunology, 2019, 143, AB97.	2.9	7
216	Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study. Journal of Allergy and Clinical Immunology, 2019, 143, AB97.	2.9	7

#	ARTICLE	IF	CITATIONS
217	Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3474-3481.	3.8	7
218	Phenotypes of Asthmaâ€“Chronic Obstructive Pulmonary Disease Overlap. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 645-655.	1.9	7
219	The Rational Use of Î²2-Agonists in the Management of Asthma: Maintenance, Rescue, and Emergency. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1998, 19, 613-624.	2.1	6
220	Asthma outcomes revisited. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 6-12.	2.6	6
221	Confronting the Challenge of COPD. <i>Chest</i> , 2018, 154, 984-985.	0.8	6
222	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. <i>ERJ Open Research</i> , 2020, 6, 00187-2019.	2.6	6
223	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD. <i>Chest</i> , 2021, 159, 985-995.	0.8	6
224	Clinically Significant and Comorbid Anxiety and Depression Symptoms Predict Severe Respiratory Exacerbations in Smokers: A <i>Post Hoc</i> Analysis of the COPD Gene and SPIROMICS Cohorts. <i>Annals of the American Thoracic Society</i> , 2022, 19, 143-146.	3.2	6
225	Revisiting Mild Asthma. <i>Chest</i> , 2022, 161, 26-39.	0.8	6
226	One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD)â€“Republished article. <i>Respiratory Medicine: COPD Update</i> , 2008, 4, 8-25.	0.0	5
227	Asthma control: a new perspective on the management of asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 1-3.	2.6	5
228	Arformoterol tartrate in the treatment of COPD. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 155-162.	2.5	5
229	Evaluating the Safety of COPD Medications. <i>Chest</i> , 2013, 144, 1357-1367.	0.8	5
230	Lebrikizumab in the treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 847-852.	3.1	5
231	Factors associated with depressive symptoms in uncontrolled asthmatics. <i>Journal of Asthma</i> , 2018, 55, 555-560.	1.7	5
232	New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. <i>International Journal of COPD</i> , 2018, Volume 13, 2805-2819.	2.3	5
233	The responsiveness of the Manchester Chronic Obstructive Pulmonary Disease Fatigue Scale to pulmonary rehabilitation. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231988220.	2.5	5
234	Design of a home-based intervention for Houston-area African-American adults with asthma: Methods and lessons learned from a pragmatic randomized trial. <i>Contemporary Clinical Trials</i> , 2020, 91, 105977.	1.8	5

#	ARTICLE	IF	CITATIONS
235	Eosinophilic vs. Neutrophilic Asthma. <i>Current Pulmonology Reports</i> , 2020, 9, 28-35.	1.3	5
236	Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home. <i>International Journal of COPD</i> , 2021, Volume 16, 2687-2695.	2.3	5
237	Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension [®] , [†] Delivery Technology Versus Foradil [®] Aerolizer [®] in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 21-33.	0.7	5
238	Differentiating Asthma and COPD Patients. <i>Chest</i> , 2004, 126, 654-655.	0.8	4
239	Influenza vaccine in patients with asthma. <i>Expert Review of Vaccines</i> , 2006, 5, 111-118.	4.4	4
240	Guest Editorial. <i>Respiratory Medicine</i> , 2012, 106, S1-S2.	2.9	4
241	Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 285-299.	2.4	4
242	Determinants of lung function improvement with omalizumab in adults with allergic asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2068-2070.	3.8	4
243	Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. <i>Respiratory Medicine</i> , 2021, 176, 106278.	2.9	4
244	Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. <i>International Journal of COPD</i> , 2021, Volume 16, 865-875.	2.3	4
245	The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. <i>Respiratory Medicine</i> , 2022, 197, 106850.	2.9	4
246	Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1835-1843.	3.8	4
247	Efficacy Of Roflumilast In Patients Receiving Concomitant Treatments For Chronic Obstructive Pulmonary Disease Over 12 Months. , 2010, , .		3
248	Editorial. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 1-2.	2.6	3
249	Safety of inhaled long-acting anti-muscarinic agents in COPD. <i>Postgraduate Medicine</i> , 2017, 129, 500-512.	2.0	3
250	Generic medications in precision medicine in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 1-2.	2.6	3
251	Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. <i>International Journal of COPD</i> , 2018, Volume 13, 499-508.	2.3	3
252	Novel therapeutic targets and drug development for the precision treatment of COPD. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 121-128.	0.7	3

#	ARTICLE	IF	CITATIONS
253	Effects of Omalizumab on Blood Eosinophil Numbers in Patients with Allergic Asthma. Journal of Allergy and Clinical Immunology, 2019, 143, AB95.	2.9	3
254	Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1430-1436.	3.8	3
255	Efficacy Of Roflumilast In Elderly Patients With Chronic Obstructive Pulmonary Disease. , 2011, , .		2
256	The Saudi guidelines for chronic obstructive pulmonary disease: A fresh "Real-World" approach to COPD. Annals of Thoracic Medicine, 2014, 9, 53.	1.8	2
257	Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma. Journal of Allergy and Clinical Immunology, 2016, 137, AB13.	2.9	2
258	Decreased Exacerbations and Improvement in Asthma Symptom Control in Asthma COPD Overlap Treated With Omalizumab: Data From the Prospero Cohort Study. Chest, 2017, 152, A776.	0.8	2
259	Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. International Journal of COPD, 2018, Volume 14, 117-127.	2.3	2
260	DUPILUMAB REDUCES SEVERE ASTHMA EXACERBATION RATE AND IMPROVES LUNG FUNCTION REGARDLESS OF AGE AT ONSET OF ASTHMA: THE LIBERTY ASTHMA QUEST STUDY. Chest, 2019, 156, A936-A939.	0.8	2
261	The challenge of differentiating asthma from chronic obstructive pulmonary disease. Managed Care, 2005, 14, 9-15; discussion 24-6.	0.3	2
262	Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest, 2022, 162, 297-308.	0.8	2
263	Impact of influenza infection on the short- and long-term health of patients with chronic obstructive pulmonary disease. Journal of Medical Economics, 2022, 25, 930-939.	2.1	2
264	Inhaled Salmeterol/Fluticasone Propionate Combination in Chronic Obstructive Pulmonary Disease. Treatments in Respiratory Medicine, 2002, 1, 283-283.	1.2	1
265	FEV1 Response to Levalbuterol vs Racemic Albuterol in Acute Severe Asthma. Chest, 2004, 126, 722S.	0.8	1
266	Efficacy Of Roflumilast In Current And Former Smokers With Chronic Obstructive Pulmonary Disease. , 2011, , .		1
267	Inhibition Of Airway Mucus Hypersecretion And Inflammation With Bio-11006, A Novel Dual Action Drug. Results In Improvement Of Indices Of Bronchitis And Lung Function In Chronic Obstructive Pulmonary Disease (COPD). , 2011, , .		1
268	A Better Way to Assess Bronchoreversibility: Response. Chest, 2012, 141, 1118-1119.	0.8	1
269	The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting. Journal of Allergy and Clinical Immunology, 2016, 137, AB256.	2.9	1
270	Response to Omalizumab Observed Over Wide Range of Blood Eosinophil Levels. Journal of Allergy and Clinical Immunology, 2018, 141, AB15.	2.9	1

#	ARTICLE	IF	CITATIONS
271	EFFECTS OF PULMONARY REHABILITATION IN COPD PATIENTS AND PERCEIVED HEALTH STATUS. Chest, 2018, 154, 982A-983A.	0.8	1
272	DUPILUMAB REDUCES SEVERE EXACERBATIONS IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA WITH AND WITHOUT EARLY IMPROVEMENTS IN LUNG FUNCTION. Chest, 2019, 156, A929-A932.	0.8	1
273	RESPONSE TO OMALIZUMAB TREATMENT IN PATIENTS WITH FIXED AIRFLOW OBSTRUCTION. Chest, 2019, 156, A933-A935.	0.8	1
274	Editorial. Current Opinion in Pulmonary Medicine, 2020, 26, 1-2.	2.6	1
275	CAPTAIN STUDY: EFFECT OF BASELINE LUNG FUNCTION ON RESPONSE TO TRIPLE THERAPY IN PATIENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID/LONG-ACTING BETA2-AGONIST THERAPY. Chest, 2020, 158, A2621-A2625.	0.8	1
276	Once-daily, single-inhale fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study. Journal of Allergy and Clinical Immunology, 2020, 145, AB241.	2.9	1
277	Step-up to high dose fluticasone furoate in combination with long-acting bronchodilator in inadequately controlled asthma: the CAPTAIN study. Journal of Allergy and Clinical Immunology, 2020, 145, AB24.	2.9	1
278	Effect of the DP2 antagonist, GB001, on asthma worsening in patients with mild-moderate asthma. Journal of Allergy and Clinical Immunology, 2020, 145, AB20.	2.9	1
279	Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. International Journal of COPD, 2021, Volume 16, 1925-1938.	2.3	1
280	InforMing the PATHway of COPD Treatment (IMPACT Trial) Single-Inhale Triple Therapy (Fluticasone) Tj ETQqO 0 0 rgBT /Overlock 10 Tf s in Patients With COPD: Analysis of the Western Europe and North America Regions. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 76-90.	0.7	1
281	Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study. , 2018, , .		1
282	Biologics targeting type 2 inflammation in severe asthma. , 2019, , 285-303.		1
283	Editorial: Dealing with asthma during the turbulent times of coronavirus disease-2019. Current Opinion in Pulmonary Medicine, 2021, 27, 1-2.	2.6	1
284	Characterising asthma exacerbations in the CAPTAIN trial. , 2020, , .		1
285	Elevated Risk of Chronic Respiratory Conditions within 60 Days of COVID-19 Hospitalization in Veterans. Healthcare (Switzerland), 2022, 10, 300.	2.0	1
286	Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team. Postgraduate Medicine, 2022, 134, 152-159.	2.0	1
287	A Full Beta2-Agonist is More Effective Than a Partial Agonist in Acute Severe Asthma. Chest, 2004, 126, 722S.	0.8	0
288	Maximal Partial Expiratory Flow is More Sensitive than Maximal Full Expiratory Flow and FEV1 in Determining Bronchodilator Response. Chest, 2004, 126, 799S.	0.8	0

#	ARTICLE	IF	CITATIONS
289	Ipratropium Bromide HFA. Treatments in Respiratory Medicine, 2005, 4, 221-222.	1.4	0
290	PHARMACOECONOMIC OUTCOMES OF LEVALBUTEROL AND RACEMIC ALBUTEROL IN INPATIENTS REQUIRING NEBULIZATION (POLARIS). Chest, 2006, 130, 181S.	0.8	0
291	Bronchodilators: Beta2-Agonists and Anticholinergics. , 2008, , 241-250.		0
292	Economic Burden Of Comorbid Cardiovascular Disease (CVD) In Chronic Obstructive Pulmonary Disease (COPD) Patients In A Managed Care Population. , 2010, , .		0
293	Gender Differences In Airway Dimensions On CT In Smokers With COPD. , 2010, , .		0
294	Variability In Lung Function In Subjects Receiving Maintenance Therapy. , 2011, , .		0
295	Characteristics Of Asthmatics With Depression. , 2011, , .		0
296	Pharmacological Therapy: Bronchodilators. , 2011, , 99-114.		0
297	Fatigue In COPD Is Significantly Associated With Exacerbations; Data From The Eclipse Cohort Study. , 2011, , .		0
298	The COPD Pipeline XII. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 387-391.	1.6	0
299	Improved Health Related Quality of Life Outcomes in Subjects With Moderate to Severe COPD Treated With Nebulized Arformoterol Tartrate: Results From a 52-Week Trial. Chest, 2013, 144, 736A.	0.8	0
300	A Large Simple Safety Study of Nebulized Arformoterol Tartrate: Incidence and Risk of Protocol-Defined COPD Exacerbations. Chest, 2013, 144, 735A.	0.8	0
301	A Large Simple Safety Study of Nebulized Arformoterol Tartrate: Risk of Respiratory-Related Deaths and COPD Exacerbation-Related Hospitalizations by Smoking Status, Age, and Disease Severity. Chest, 2013, 144, 714A.	0.8	0
302	Optimizing care of your patients with COPD. Nursing (Auckland, N Z), 2014, , 7.	2.0	0
303	Addition of Arformoterol Tartrate (ARF), a Long-Acting Î²2 Agonist (LABA), to Tiotropium Bromide (TIO) Improves Outcomes of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With TIO Alone or Placebo (PBO). Chest, 2015, 148, 742A.	0.8	0
304	Predictors of Noncompletion of Pulmonary Rehabilitation Program in Patients With COPD. Chest, 2016, 150, 1128A.	0.8	0
305	Type 2 Biomarkers Define a Prevalent Phenotype in Moderate-to-Severe, Uncontrolled Asthma Patients: A Pooled Analysis from Lebrikizumab All-Comers Phase 2 Trials. Journal of Allergy and Clinical Immunology, 2016, 137, AB108.	2.9	0
306	Measuring Exhaled Nitric Oxide (FeNO) Improves Assessment of Airway Inflammation and Guides Stepwise Treatment Decisions. Journal of Allergy and Clinical Immunology, 2017, 139, AB196.	2.9	0

#	ARTICLE	IF	CITATIONS
307	Procalcitonin in Chronic Obstructive Pulmonary Disease Exacerbations: Is It Ready for Primetime Use?. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1757-1758.	3.2	0
308	Predictors of Quality of Life in COPD Patients Following Pulmonary Rehabilitation. <i>Chest</i> , 2017, 152, A979.	0.8	0
309	Seeing the Forest for the Trees: A Case of an Atypical Bacterial Pneumonia Leading to the Diagnosis of COVID. <i>Chest</i> , 2017, 152, A172.	0.8	0
310	Efficacy of Perforomist (Formoterol Fumarate) Inhalation Solution in Improving Lung Function in Moderate to Severe COPD. <i>Chest</i> , 2017, 152, A769.	0.8	0
311	THE RESPONSIVENESS OF THE MANCHESTER COPD FATIGUE SCALE. <i>Chest</i> , 2018, 154, 984A-985A.	0.8	0
312	SIGNIFICANT IMPROVEMENT IN LUNG FUNCTION FOLLOWING 16 WEEKS OF OMALIZUMAB TREATMENT: POOLED ANALYSES IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA. <i>Chest</i> , 2018, 154, 2A-3A.	0.8	0
313	COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL. <i>Chest</i> , 2019, 156, A475-A478.	0.8	0
314	DUAL-COMBINATION MAINTENANCE INHALER PREFERENCES IN ASTHMA AND COPD: A PATIENT-CENTERED BENEFIT-RISK ASSESSMENT. <i>Chest</i> , 2019, 156, A9-A10.	0.8	0
315	EFFECT OF AGE ON EFFICACY AND SAFETY OF ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN PATIENTS WITH COPD: A POST-HOC ANALYSIS OF THE IMPACT TRIAL. <i>Chest</i> , 2019, 156, A1750-A1754.	0.8	0
316	Response. <i>Chest</i> , 2019, 156, 1276.	0.8	0
317	MOVING PULMONARY REHABILITATION INTO HOME: A VETERANS HOSPITAL ADMINISTRATION INITIATIVE TO DEVELOP A HOME-BASED PULMONARY REHABILITATION PROGRAM. <i>Chest</i> , 2020, 158, A1298.	0.8	0
318	Corticosteroid Use Across Asthma Health-Care Providers: A Real-world Experience. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB114.	2.9	0
319	CAPTAIN STUDY: ASSOCIATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS WITH LUNG FUNCTION AND PATIENT-REPORTED OUTCOMES IN A LARGE RANDOMIZED PHASE III CLINICAL TRIAL. <i>Chest</i> , 2020, 158, A35-A38.	0.8	0
320	A CASE OF MAC IN A PATIENT WITH CHRONIC SILICOSIS. <i>Chest</i> , 2020, 158, A2521.	0.8	0
321	IMPACT OF CHANGES IN THE 2019 GINA TREATMENT CLASSIFICATION: ASSESSMENT IN A REAL-WORLD SETTING. <i>Chest</i> , 2020, 158, A1-A2.	0.8	0
322	Expert Advice on Managing Severe Asthma: An Interactive Decision Support Tool Provides Real-Time Expert Recommendations. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, AB39.	2.9	0
323	DEVELOPMENT AND VALIDATION OF A PATIENT-BASED MEASURE OF COPD STABILITY. <i>Chest</i> , 2006, 130, 98S.	0.8	0
324	Th2 lymphocyte potassium channels in asthma. <i>FASEB Journal</i> , 2011, 25, 945.7.	0.5	0

#	ARTICLE	IF	CITATIONS
325	Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status. , 2015, , .		0
326	Asthma and Aging. , 2016, , 397-428.		0
327	LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma. , 2016, , .		0
328	The responsiveness of the depression, anxiety and stress-21 items scale to pulmonary rehabilitation program. , 2016, , .		0
329	Long-term benefits of pulmonary rehabilitation in COPD patients: 2 year follow-up. , 2017, , .		0
330	The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma. , 2017, , .		0
331	Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study. , 2018, , .		0
332	Practical Considerations in Management of Allergic Asthma. Respiratory Medicine, 2020, , 155-180.	0.1	0
333	Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies. , 2019, , .		0
334	CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA. , 2020, , .		0
335	CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA. , 2020, , .		0
336	Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements. , 2020, , .		0
337	Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function. , 2020, , .		0
338	COPD Management in the Primary Care Setting. Journal of Family Practice, 2018, 67, S27-S32.	0.2	0